Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / LTBP2

LTBP2

Basics

Aliases:
This biomarker is also known as:
  • C14orf141,
  • GLC3D,
  • latent transforming growth factor beta binding protein 2,
  • LTBP-2,
  • Latent-transforming growth factor beta-binding protein 2,
  • MSTP031,
  • chromosome 14 open reading frame 141,
  • LTBP3,

View in BioMuta

Description…

LTBP2, the largest member of the latent transforming growth factor (TGF)-beta binding protein family, possesses unique regions and is most similar to the fibrillins. It has thus been suggested that it may have multiple functions: as a member of the TGF-beta latent complex, as a structural component of microfibrils, and a role in cell adhesion. LTBP2 forms part of the large latent transforming growth factor beta precursor complex; removal is essential for activation of complex. It is expressed in lung, weakly expressed in heart, placenta, liver and skeletal muscle.

Attributes

QA State: Curated
Type: Protein
Short Name:
HGNC Name: LTBP2

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Ovary

Attributes

Phase: One
QA State: Under Review

Overview

No additional ovarian data available.

Performance Comment

LTBP2 was one of 50 tumor vasculature-associated genes with transmembrane or secreted protein products identified through expression profiling of ovarian cancer vascular cells. These 50 tumor vascular markers (TVMs) also had low or no expression in normal tissues. LTBP2 was not in the group of 13 selected for further validation.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

2015 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place October 15–16, 2015 in Bethesda, Maryland.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to http://grants.nih.gov /grants/guide/ pa-files/ PAR-15-289.html.

Announcement 04/08/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held October 15-16, 2015 on the NCI campus. More information will be available later this summer.